Johnson & Johnson (NYSE:JNJ - Get Free Report) had its target price lifted by equities research analysts at Barclays from $165.00 to $176.00 in a research report issued on Thursday,Benzinga reports. The firm presently has an "equal weight" rating on the stock. Barclays's target price would indicate a potential upside of 7.55% from the stock's previous close.
Other equities analysts also recently issued research reports about the company. Guggenheim increased their price objective on Johnson & Johnson from $164.00 to $167.00 and gave the stock a "neutral" rating in a report on Thursday. Raymond James Financial decreased their price objective on shares of Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating for the company in a report on Monday, April 14th. Leerink Partners downgraded Johnson & Johnson from an "outperform" rating to a "market perform" rating and reduced their price objective for the stock from $169.00 to $153.00 in a research report on Tuesday, May 13th. Leerink Partnrs lowered Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, May 13th. Finally, Benchmark raised Johnson & Johnson to a "strong-buy" rating in a research report on Thursday, April 24th. Eleven investment analysts have rated the stock with a hold rating, nine have given a buy rating and three have given a strong buy rating to the company's stock. According to MarketBeat, Johnson & Johnson has an average rating of "Moderate Buy" and a consensus target price of $174.11.
Read Our Latest Research Report on JNJ
Johnson & Johnson Price Performance
NYSE:JNJ traded up $0.67 during midday trading on Thursday, hitting $163.65. 9,764,459 shares of the stock were exchanged, compared to its average volume of 8,146,244. The company has a market capitalization of $393.75 billion, a price-to-earnings ratio of 17.50, a P/E/G ratio of 2.21 and a beta of 0.41. The company has a current ratio of 1.26, a quick ratio of 1.03 and a debt-to-equity ratio of 0.49. Johnson & Johnson has a one year low of $140.68 and a one year high of $169.99. The business has a 50-day moving average price of $154.10 and a two-hundred day moving average price of $154.84.
Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, topping the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a return on equity of 33.07% and a net margin of 25.00%. The business had revenue of $23.74 billion during the quarter, compared to analyst estimates of $22.85 billion. During the same period last year, the company posted $2.82 EPS. The company's revenue was up 5.8% compared to the same quarter last year. Sell-side analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.
Institutional Investors Weigh In On Johnson & Johnson
A number of large investors have recently added to or reduced their stakes in the business. Lantz Financial LLC grew its position in shares of Johnson & Johnson by 3.3% during the 1st quarter. Lantz Financial LLC now owns 11,974 shares of the company's stock worth $1,986,000 after purchasing an additional 377 shares in the last quarter. Sulzberger Capital Advisors Inc. bought a new stake in shares of Johnson & Johnson in the 4th quarter valued at about $453,000. Joel Isaacson & Co. LLC increased its position in Johnson & Johnson by 3.5% during the 1st quarter. Joel Isaacson & Co. LLC now owns 74,132 shares of the company's stock valued at $12,294,000 after purchasing an additional 2,526 shares during the period. State of Wyoming grew its holdings in Johnson & Johnson by 205,580.0% during the 4th quarter. State of Wyoming now owns 10,284 shares of the company's stock worth $1,487,000 after acquiring an additional 10,279 shares during the period. Finally, Range Financial Group LLC grew its position in shares of Johnson & Johnson by 18.9% during the 1st quarter. Range Financial Group LLC now owns 15,886 shares of the company's stock worth $2,635,000 after buying an additional 2,529 shares during the period. Institutional investors own 69.55% of the company's stock.
About Johnson & Johnson
(
Get Free Report)
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
See Also
Before you consider Johnson & Johnson, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.
While Johnson & Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
